GI
CMMB

GAMMA Investing’s Chemomab Therapeutics CMMB Stock Holding History

GAMMA Investing’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.68K Sell
4,740
-2,839
-37% -$4.79K ﹤0.01% 3313
2026
Q1 		$11.9K Buy
7,579
+5,065
+201% +$8.65K ﹤0.01% 2979
2025
Q4 		$4.15K Buy
2,514
+1,847
+277% +$4.9K ﹤0.01% 3360
2025
Q3 		$1.75K Sell
667
-2,536
-79% -$9.35K ﹤0.01% 3486
2025
Q2 		$14.9K Buy
3,203
+446
+16% +$2.21K ﹤0.01% 2613
2025
Q1 		$12K Buy
2,757
+1,482
+116% +$10.4K ﹤0.01% 2662
2024
Q4 		$9.23K Buy
+1,275
New +$8.05K ﹤0.01% 2656

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GAMMA Investing's CMMB Position: Q2 2026 in Review

GAMMA Investing reduced its Chemomab Therapeutics (CMMB) stake by 37% in Q2 2026, selling an estimated $4.79K and leaving 4,740 shares worth $7.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3313.

GAMMA Investing first reported a position in CMMB in Q4 2024 and has held it in 7 quarters since. The position peaked at $14.9K in Q2 2025. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • GAMMA Investing held 4,740 shares of Chemomab Therapeutics worth $7.68K as of Q2 2026.
  • GAMMA Investing sold 2,839 Chemomab Therapeutics shares in Q2 2026, an estimated $4.79K.
  • Chemomab Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3313 holding.
  • GAMMA Investing first reported a position in Chemomab Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GAMMA Investing's Chemomab Therapeutics position peaked at $14.9K in Q2 2025.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.